Literature DB >> 18058255

Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.

Jian Ming Fan1, Qiao Zhang, Jun Xu, Sha Zhu, Tao Ke, De Fu Gao, Yu Bao Xu.   

Abstract

The gene encoding MAP30 protein was cloned from bitter melon and recombinant MAP30 was expressed and purified. The human hepatoma G2.2.15 cells were exposed to different concentrations of MAP30. MTT assay was used to evaluate the cytotoxicity of the drugs and real-time PCR and Southern hybridization were applied to quantify extracellular HBV DNA and replicative intermediates intracellular and cccDNA in nucleus. HBsAg and HBeAg were assessed by enzyme-linked immunosorbent assay (ELISA). The results showed that exposure of HepG2.2.15 cells to MAP30 resulted in inhibition of HBV DNA replication and HBsAg secretion. After exposed to three different concentrations of MAP30 for 2, 4, 6, and 8 days respectively, the inhibition rates of extracellular HBV DNA, HBsAg, and HBeAg of each concentration decreased significantly (P < 0.05). After 9 days of treatment, the inhibition rates of extracellular HBV DNA of the different concentrations differed greatly (P < 0.001). The MAP30 could inhibit the production of HBV (P < 0.01) dose-dependently. The expression of HBsAg was significantly decreased by MAP30 dose-dependently (P < 0.001) and time-dependently (P < 0.001). Lower dose of MAP30 (8.0 microg/ml) could inhibit the expression of HBsAg and HBeAg.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058255     DOI: 10.1007/s11033-007-9191-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  27 in total

1.  Current treatments for hepatitis.

Authors:  Jean Fleming
Journal:  J Infus Nurs       Date:  2002 Nov-Dec

Review 2.  Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma.

Authors:  Okio Hino; Kazunori Kajino; Tomoyuki Umeda; Yasuo Arakawa
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

Review 3.  Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.

Authors:  F von Weizsäcker; S Wieland; J Köck; W B Offensperger; S Offensperger; D Moradpour; H E Blum
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

Review 4.  The molecular biology of the hepatitis B viruses.

Authors:  D Ganem; H E Varmus
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

Review 5.  Management of chronic hepatitis B infection: an update.

Authors:  T N Mazumdar
Journal:  J Indian Med Assoc       Date:  2001-06

6.  HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.

Authors:  Chun Tao Wai; Chi-Jen Chu; Munira Hussain; Anna S F Lok
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

Review 7.  Current state of interferon therapy in the treatment of chronic hepatitis B.

Authors:  Michael P Manns
Journal:  Semin Liver Dis       Date:  2002       Impact factor: 6.115

8.  An epidemiologic study of hepatocellular carcinoma in Canada.

Authors:  Susie elSaadany; Martin Tepper; Yang Mao; Robert Semenciw; Antonio Giulivi
Journal:  Can J Public Health       Date:  2002 Nov-Dec

Review 9.  The National Cancer Institute: cancer drug discovery and development program.

Authors:  M R Grever; S A Schepartz; B A Chabner
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

10.  Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.

Authors:  Leonieke M M Wolters; Bettina E Hansen; Hubert G M Niesters; Robert A de Man
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-09       Impact factor: 2.566

View more
  7 in total

Review 1.  Ribosome inactivating proteins from plants inhibiting viruses.

Authors:  Inderdeep Kaur; R C Gupta; Munish Puri
Journal:  Virol Sin       Date:  2011-12-10       Impact factor: 4.327

2.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

Review 3.  Anti-hepatitis B activities of Myanmar medicinal plants: a narrative review of current evidence.

Authors:  Ye Htut Linn; Win Win Ei; Lwin Mon Mon Myint; Khin Maung Lwin
Journal:  Virusdisease       Date:  2021-07-14

4.  IFN-CSP inhibiting hepatitis B virus in HepG2.2.15 cells involves JAK-STAT signal pathway.

Authors:  Xuemei Lu; Jie Wang; Xiaobao Jin; Yanting Huang; Wenting Zeng; Jiayong Zhu
Journal:  Biomed Res Int       Date:  2015-03-16       Impact factor: 3.411

5.  Novel purification method and antibiotic activity of recombinant Momordica charantia MAP30.

Authors:  Ching-Dong Chang; Ping-Yuan Lin; Yo-Chia Chen; Han-Hsiang Huang; Wen-Ling Shih
Journal:  3 Biotech       Date:  2017-04-07       Impact factor: 2.406

Review 6.  Antiviral Activity of Ribosome-Inactivating Proteins.

Authors:  Lucía Citores; Rosario Iglesias; José M Ferreras
Journal:  Toxins (Basel)       Date:  2021-01-22       Impact factor: 4.546

7.  A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.

Authors:  Yao Meng; Sen Lin; Shuangfeng Liu; Xiang Fan; Gangrui Li; Yanfa Meng
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.